Citigroup’s Atara Biotherapeutics ATRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5 | Buy |
+1
| New | +$6 | ﹤0.01% | 5774 |
|
|
2025
Q1 | – | Sell |
-2
| Closed | -$27 | – | 5570 |
|
|
2024
Q4 | $27 | Sell |
2
-6
| -75% | -$63 | ﹤0.01% | 5740 |
|
|
2024
Q3 | $65 | Sell |
8
-3,164
| -100% | -$27.1K | ﹤0.01% | 5550 |
|
|
2024
Q2 | $27K | Buy |
3,172
+2,425
| +325% | +$36.5K | ﹤0.01% | 4905 |
|
|
2024
Q1 | $13K | Buy |
747
+187
| +33% | +$3.32K | ﹤0.01% | 5139 |
|
|
2023
Q4 | $7.18K | Sell |
560
-17,564
| -97% | -$410K | ﹤0.01% | 5270 |
|
|
2023
Q3 | $671K | Sell |
18,124
-1,146
| -6% | -$51K | ﹤0.01% | 2833 |
|
|
2023
Q2 | $776K | Sell |
19,270
-17,179
| -47% | -$971K | ﹤0.01% | 3035 |
|
|
2023
Q1 | $2.64M | Sell |
36,449
-4,568
| -11% | -$443K | ﹤0.01% | 1840 |
|
|
2022
Q4 | $3.36M | Sell |
41,017
-10,568
| -20% | -$1.1M | ﹤0.01% | 1702 |
|
|
2022
Q3 | $4.88M | Buy |
51,585
+10,243
| +25% | +$1.15M | ﹤0.01% | 1582 |
|
|
2022
Q2 | $8.05M | Buy |
41,342
+6,736
| +19% | +$1.1M | 0.01% | 1262 |
|
|
2022
Q1 | $8.04M | Sell |
34,606
-5,925
| -15% | -$1.89M | ﹤0.01% | 1403 |
|
|
2021
Q4 | $16M | Buy |
40,531
+29,697
| +274% | +$12.5M | 0.01% | 1141 |
|
|
2021
Q3 | $4.85M | Sell |
10,834
-6,340
| -37% | -$2.27M | ﹤0.01% | 1849 |
|
|
2021
Q2 | $6.68M | Buy |
17,174
+45
| +0.3% | +$16.1K | ﹤0.01% | 1685 |
|
|
2021
Q1 | $6.15M | Sell |
17,129
-33,422
| -66% | -$14.8M | ﹤0.01% | 1653 |
|
|
2020
Q4 | $24.8M | Buy |
50,551
+43,536
| +621% | +$20.1M | 0.01% | 901 |
|
|
2020
Q3 | $2.27M | Sell |
7,015
-1,984
| -22% | -$676K | ﹤0.01% | 2539 |
|
|
2020
Q2 | $3.28M | Buy |
8,999
+393
| +5% | +$99.3K | ﹤0.01% | 2267 |
|
|
2020
Q1 | $1.83M | Buy |
8,606
+1,325
| +18% | +$421K | ﹤0.01% | 2559 |
|
|
2019
Q4 | $3M | Buy |
7,281
+1,224
| +20% | +$422K | ﹤0.01% | 2538 |
|
|
2019
Q3 | $2.14M | Buy |
6,057
+3,285
| +119% | +$1.23M | ﹤0.01% | 2796 |
|
|
2019
Q2 | $1.39M | Buy |
2,772
+2,166
| +357% | +$1.53M | ﹤0.01% | 3243 |
|
|
2019
Q1 | $602K | Sell |
606
-3,884
| -87% | -$3.61M | ﹤0.01% | 3979 |
|
|
2018
Q4 | $3.9M | Buy |
4,490
+1,147
| +34% | +$1.07M | ﹤0.01% | 2051 |
|
|
2018
Q3 | $3.46M | Buy |
3,343
+1,118
| +50% | +$1.09M | ﹤0.01% | 2212 |
|
|
2018
Q2 | $2.04M | Sell |
2,225
-158
| -7% | -$170K | ﹤0.01% | 2658 |
|
|
2018
Q1 | $2.32M | Buy |
2,383
+2,374
| +26,378% | +$2.16M | ﹤0.01% | 2478 |
|
|
2017
Q4 | $4K | Buy |
9
+6
| +200% | +$2.22K | ﹤0.01% | 7267 |
|
|
2017
Q3 | $1K | Sell |
3
-4
| -57% | -$1.51K | ﹤0.01% | 7099 |
|
|
2017
Q2 | $2K | Sell |
7
-3
| -30% | -$1.16K | ﹤0.01% | 6961 |
|
|
2017
Q1 | $5K | Sell |
10
-1,756
| -99% | -$727K | ﹤0.01% | 6769 |
|
|
2016
Q4 | $627K | Buy |
1,766
+1,678
| +1,907% | +$711K | ﹤0.01% | 4149 |
|
|
2016
Q3 | $47K | Sell |
88
-152
| -63% | -$82.5K | ﹤0.01% | 5696 |
|
|
2016
Q2 | $135K | Sell |
240
-239
| -50% | -$115K | ﹤0.01% | 4829 |
|
|
2016
Q1 | $228K | Buy |
479
+415
| +648% | +$187K | ﹤0.01% | 4961 |
|
|
2015
Q4 | $42K | Sell |
64
-567
| -90% | -$429K | ﹤0.01% | 6055 |
|
|
2015
Q3 | $496K | Buy |
631
+620
| +5,636% | +$756K | ﹤0.01% | 3755 |
|
|
2015
Q2 | $14K | Sell |
11
-1,035
| -99% | -$1.19M | ﹤0.01% | 6284 |
|
|
2015
Q1 | $1.09M | Buy |
1,046
+1,007
| +2,582% | +$666K | ﹤0.01% | 3009 |
|
|
2014
Q4 | $26K | Buy |
+39
| New | +$23.8K | ﹤0.01% | 6083 |
|
Other funds holding ATRA
RG
VCM
EC
Citigroup's ATRA Position: Q1 2026 in Review
Citigroup opened a new position in Atara Biotherapeutics (ATRA) in Q1 2026: 1 share worth $5. The stake represents ﹤0.01% of the portfolio and ranks #5774 among its holdings. This is a return to the name: Citigroup previously reported a position in ATRA as recently as Q4 2024.
Citigroup first reported a position in ATRA in Q4 2014 and has held it in 42 quarters since. The position peaked at $24.8M in Q4 2020. 33 funds tracked by Wall St. Rank hold ATRA as of Q1 2026.
- Citigroup held 1 share of Atara Biotherapeutics worth $5 as of Q1 2026.
- Atara Biotherapeutics was a new Citigroup position in Q1 2026.
- Atara Biotherapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5774 holding.
- Citigroup first reported a position in Atara Biotherapeutics in Q4 2014 and has held it in 42 quarters since.
- Citigroup's Atara Biotherapeutics position peaked at $24.8M in Q4 2020.
- 33 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.